PharmaVOICE - 
March 2005
Purchase Issue

In Every Issue
What’s New
HMP Launches Arthritis Practitioner HMP Communications is launching Arthritis Practitioner [...]
By
E-Media
ISB and IBM launch Human Proteome Folding Project on World [...]
By
Talent Pool
Pharma POOL Dr. Mahdi B. Fawzi Dr. Frank S. Walsh [...]
By
Letter from the Editor
Facing industry challenges Healthcare advertising agencies, service providers, and companies [...]
By

Taren Grom, Editor

What’s on Your Mind — Opinions
What’s on your Mind Opinions Monitoring Drug Safety The industry [...]
By
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Pharmaceutical Companies [...]
By

On The Cover

Making Metrics Matter — The Changing Paradigm of R&D Metrics
Making Metrics Matter The Changing Paradigm of R&D Metrics As the pharmaceutical industry comes under greater scrutiny across the board, everything from discovery processes to R&D productivity to profit margins is subject to review. In response, top industry executives are reexamining the efficiency of their R&D operations. In an effort to self-scrutinize, many companies are [...]
By

Elisabeth Pena

Features

For Art’s Sake
Each month, this department pays homage to memorable advertising and marketing campaigns. The highlighted executions have been identified by leading creative executives for their noteworthy use of copy, art, photography, whimsy, uniqueness, etc. — in combination or as single branding elements. Creating good pharmaceutical advertising and marketing requires agencies to think out of the box [...]
By
Global Perspective
Is Japan on the Verge of a Biotech Boom? A growing number of biopharma start-up companies are looking beyond the United States and Europe for business opportunities. And one market that is generating a lot of buzz in biotech today is Japan. One of the more under-reported business stories of the past year has been [...]
By
The Asthma Market Breathes Easier
The Asthma Market Breathes Easier The approach to treating asthma continues to evolve. Rescue bronchodilator therapies are giving way, both in medical practice and in the market, to prophylactic strategies, which include inhaled corticosteroids, long-acting beta2 agonists, and leukotriene antagonists. Sales of combination therapies, leukotriene antagonists, and the introduction of more expensive novel agents are [...]
By

Denise Myshko

Dr. Mark Ahn — Poetic Science
Mark Ahn — Poetic Science For Mark Ahn, Ph.D., leadership is less about the power of one individual and more about the creation of heroic teams. Using a mix of literature, history, and traditional business skills, Dr. Ahn has found ways to unlock the imagination of his colleagues and employees at Hana Biosciences to build [...]
By

Kim Ribbink

Cautious Capital
The funding environment for biotech and start-up companies has improved considerably during the past few years. But venture capital investors are more cautious and more demanding than ever before. Karen Boezi Venture capital investors will increasingly be focused on capital efficiency and reducing risk. We believe this focus will continue to favor product companies over [...]
By

Lisa Dress

Confluence Marketing: A Union of Forces for a Shared Outcome
Confluence Marketing: A Union of Forces for a Shared Outcome Confluence marketing is a philosophy and a process for sharing ideas across key customer groups and breaking down traditional divides. It is precisely at the confluence of these groups that true marketing power is unleashed, and when the marketing agenda should be set. VIEW on [...]
By
Table of Contents
on the cover Making metrics matter: The changing paradigm of R&D metrics As the pharma industry comes under greater scrutiny, everything from discovery processes to R&D productivity to profit margins is subject to review. Metrics systems are being implemented to realize efficiencies and boost productivity. 8 FEATURES Cautious capital The funding environment for biotech and [...]
By
FEEDBACK